{"id":"mcapox-plus-cetuximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Skin rash"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Dermatitis acneiform"},{"rate":"10-30%","effect":"Mucositis"},{"rate":"10-30%","effect":"Anorexia"},{"rate":"10-30%","effect":"Weight loss"},{"rate":"5-20%","effect":"Hypomagnesemia"},{"rate":"5-20%","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"mCapOX is a platinum-based chemotherapy drug that forms platinum-DNA adducts, thereby inhibiting DNA replication and transcription. Cetuximab is a chimeric monoclonal antibody that binds to the extracellular domain of EGFR, preventing its activation and subsequent signaling pathways that promote cell proliferation and survival.","oneSentence":"mCapOX is a chemotherapy drug that works by inhibiting DNA replication, while cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:24.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT05022030","phase":"PHASE2","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-21","conditions":"Colo-rectal Cancer, Capecitabine, Cetuximab","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mCapOX plus cetuximab","genericName":"mCapOX plus cetuximab","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mCapOX is a chemotherapy drug that works by inhibiting DNA replication, while cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Used for Metastatic colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}